(1-Methyl-hexyl)-aethyl-aether | 67931-48-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (1-Methyl-hexyl)-aethyl-aether
• 英文别名: 2-ethoxy-heptane；Heptanol-(2)-aethylaether；2-Aethoxy-heptan；2-Ethoxyheptane
• CAS: 67931-48-0
• 化学式: C₉H₂₀O
• 分子量: 144.257
• InChiKey: DGDYQZJLQRCAFA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  10
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  1-氯-1-乙氧基乙烷 、 正戊基溴化镁 生成 (1-Methyl-hexyl)-aethyl-aether
  参考文献：
  名称：

  Watermann et al., Recueil des Travaux Chimiques des Pays-Bas, 1937, vol. 56, p. 441

  摘要：

  DOI：

文献信息

• Method for Producing Compound Containing BIS (Perfluoroalkylsulfonyl) Methyl Group and Salt Thereof, and Solid Electrolyte Membrane Produced Using Same
  申请人：CENTRAL GLASS COMPANY, LIMITED

  公开号：US20150266816A1

  公开（公告）日：2015-09-24

  [Problem] To provide a method for producing a compound having a bis(trifluoroalkanesulfonyl)methyl group, which is a compound having a high acidity degree and hydrophobicity and useful as a raw material compound for a resin, and a salt thereof in a simple manner. [Solution] A method for producing a compound containing a bis(perfluoroalkylsulfonyl)methyl group and represented by the following formula and a salt of the compound. (Rf represents a perfluoroalkyl group having 1 to 12 carbon atoms. A represents a monovalent organic group. Y represents a single bond or a C 1 -C 4 linear, C 3 -C 4 branched or C 3 -C 4 cyclic alkylene group wherein each of some or all of hydrogen atoms may be substituted with a fluorine atom, a chlorine atom, a bromine atom or an iodine atom and an ether bond or an ester bond may be contained.)

  提供一种简单的方法，用于生产具有高酸度和疏水性的双(三氟烷磺酰基)甲基基团的化合物，该化合物可作为树脂的原料化合物，并提供该化合物的盐。生产含有双(全氟烷基磺酰基)甲基基团的化合物及其盐的方法如下所示： （Rf代表具有1至12个碳原子的全氟烷基基团。A代表一价有机基团。Y代表单键或C1-C4线性、C3-C4支链或C3-C4环烷基基团，其中部分或全部氢原子可被氟原子、氯原子、溴原子或碘原子取代，并且可能包含醚键或酯键。）
• Indole, indazole and indoline derivatives as CETP inhibitors
  申请人：Conte-Mayweg Aurelia

  公开号：US20060030613A1

  公开（公告）日：2006-02-09

  The present invention relates to compounds of formula (I): wherein —X—Y—, R 1 to R 11 and n are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prevention of diseases which are mediated by CETP inhibitors.

  本发明涉及以下式(I)的化合物： 其中-X-Y-, R1至R11和n如描述和权利要求中所定义，并且其药学上可接受的盐。这些化合物对于治疗和/或预防通过CETP抑制剂介导的疾病是有用的。
• 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents
  申请人：——

  公开号：US20030187040A1

  公开（公告）日：2003-10-02

  Compounds which are 2-ureido-1,3-thiazole derivatives of formula (I) wherein R is a halogen atom, a nitro group, an optionally substituted amino group or it is a group, optionally further substituted, selected from: i) straight or branched C1-C6 alkyl; ii) C3-C6 cycloalkyl; iii) aryl or arylalkyl with from 1 to 6 carbon atoms within the straight or branched alkyl chain; R1 is an optionally substituted group selected from: i) straight or branched C1-C6 alkyl; ii) 3 to 6 membered carbocycle or 5 to 7 membered heterocycle ring, iii) aryl or arylcarbonyl; iv) arylalkyl with from 1 to 6 carbon atoms within the straight or branched alkyl chain: R2 is hydrogen, a straight or branched C1-C4 alkyl or C2-C4 alkenyl or alkynyl group; or, taken together with the nitrogen atom to which they are bonded, R1 and R2 form a substituted or unsubstituted group selected from: i) an optionally benzocondensed or bridged 5 to 7 membered heterocycle; or ii) a 9 to 11 membered spiro-heterocyclic compound; or a pharmaceutically acceptable salt thereof; are useful for treating cell proliferative disorders associated with an altered cell dependent kinase activity.

  化合物是公式（I）的2-脲基-1,3-噻唑衍生物，其中R是卤素原子，硝基，可选择取代的氨基团或者是从以下选项中选择的可选择进一步取代的基团：i）直链或支链的C1-C6烷基；ii）C3-C6环烷基；iii）芳基或芳基烷基，在直链或支链烷基链中含有1至6个碳原子；R1是可选择取代的基团，选择自：i）直链或支链的C1-C6烷基；ii）3至6成员碳环或5至7成员杂环环，iii）芳基或芳基酰基；iv）芳基烷基，在直链或支链烷基链中含有1至6个碳原子；R2是氢，直链或支链的C1-C4烷基或C2-C4烯基或炔基；或者，与它们结合的氮原子一起，R1和R2形成一个选择自：i）可选择苯并或桥联的5至7成员杂环；或ii）9至11成员螺环杂环化合物；或其药用盐，用于治疗与改变的细胞依赖性激酶活性相关的细胞增殖异常。
• Epothilone synthesis building blocks III and IV: asymmetrically substituted acyloins and acyloin derivatives, methods for their production and methods for the production of epothilones B, D and epothilone derivatives
  申请人：——

  公开号：US20040082651A1

  公开（公告）日：2004-04-29

  The present invention is directed to novel acyloins, their derivatives, methods for their production and their use for the production of novel epothilones and their derivatives. In addition, the invention is directed to the building blocks for epothilone synthesis, methods for their production and the use of synthetic building blocks for the production of epothilones and their derivatives.

  本发明涉及新型酰亚胺、其衍生物、其生产方法以及用于生产新型依托利酮及其衍生物的方法。此外，本发明还涉及依托利酮合成的构建块、其生产方法以及用于生产依托利酮及其衍生物的合成构建块的使用。
• N-acyl-amino acid derivatives and pharmaceutical compositions containing them, intermediates and starting compounds
  申请人：MERRELL TORAUDE ET COMPAGNIE

  公开号：EP0021883A2

  公开（公告）日：1981-01-07

  ovel N-acyl amino acid derivatives are irreversible inhibitors of angiotensin-converting enzyme and have the following general Formula 1:- wherein:- Z represents an electron-withdrawing group, preferably cyano or a carbonyl-terminated functional group; X represents a group which, in combination with Z, can form a Michael acceptor after abstraction of the proton from the carbon atom adjacentto X, and preferably X is ethynyl or a fluoromethyl group; R, represents hydrogen, alkyl or phenylalkyl; and R2 represents an aminocarboxylic acid residue obtained by removal of a hydrogen atom from the amino group thereof. Novel intermediates include compounds of the following general Formula 21:- wherein A represents tert-butyl, dibenzyl or trityl, and compounds of the following general Formula 36 (being the combination of Formulae 29 and 35 herein):- wherein X1 represents ethynyl or mono-, di- or trifluoromethyl; R1 is a defined above; Re represents hydroxy, alkoxy or amino; and R10 represents hydrogen, alkyl, phenylalkyl, phenyl or p-methoxyphenyl.

  新型 N-酰基氨基酸衍生物是血管紧张素转换酶的不可逆抑制剂，通式 1 如下：- N-酰基氨基酸衍生物是血管紧张素转换酶的不可逆抑制剂。 其中 Z 代表一个抽电子基团，最好是氰基或羰基末端官能团； X 代表一个基团，该基团与 Z 结合，在从与 X 相邻的碳原子上抽取质子后可形成迈克尔受体，优选 X 为乙炔基或氟甲基； R 代表氢、烷基或苯基烷基；以及 R2 代表通过从氨基中去除一个氢原子而得到的氨基甲酸酯残基。 新型中间体包括以下通式 21：- 的化合物。 其中 A 代表叔丁基、二苄基或三苄基，以及以下通式 36 的化合物（即本文式 29 和 35 的组合）： - 其中 X1 代表乙炔基。 其中 X1 代表乙炔基或单、双或三氟甲基； R1 是上文所定义的 Re 代表羟基、烷氧基或氨基；以及 R10 代表氢、烷基、苯基烷基、苯基或对甲氧基苯基。